2015 American Transplant Congress
Induction Avoidance in 2-Haplotype-Matched White Living Kidney Transplantation
Background: We hypothesize that 2-haplotype matched white living kidney transplant recipients carry a low immunologic risk for rejection, and therefore do not give induction therapy…2015 American Transplant Congress
Medication Non-Adherence in Those Waiting for a Transplant
Purpose: Though poor medication adherence among adult kidney transplant patients is alarmingly high with distressing consequences, no one has systematically examined medication non-adherence in those…2015 American Transplant Congress
Assessment of Viral-Specific Memory T Cell Responses and Infection Rates in HLA-Sensitized (HS) Kidney Transplant Patients (Tx Pts) Treated With Everolimus & Low-Dose Tacrolimus (Eve/Tac)
Transplant Immunology & Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles.
Background: mTOR inhibitors stimulate viral-specific memory CD8+ T cell differentiation and increase viral clearance in infected Tx pts. HS pts desensitized (DES) with IVIG +…2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…2015 American Transplant Congress
Calcineurin Inhibitors (CNI) Minimization Associated With Mammalian Target of Rapamycin Inhibitors (i-mTOR) to Improve Renal Function in Renal Grafts from Uncontrolled Donation After Cardiac Death Donors (UDCDD)
INTRODUCTION: Ischemia injury in kidneys grafts from UDCDD could produce a poor renal function. Minimized blood levels of CNI associated with i-mTOR therapy could avoid…2015 American Transplant Congress
Incidence of Hepatitis B Virus Reactivation in Kidney Transplant Patients Who Received Rituximab Administration
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
OBJECTIVE:The efficacy of antiviral prophylaxis for rituximab (RIT)-associated hepatitis B virus (HBV) reactivation in patients with lymphoma has been recently reported. However, the immunological effect…2015 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…2015 American Transplant Congress
Clinical and Pathologic Predictors of Response to Belatacept Conversion
Columbia Universtiy, New York.
INTRO: Calcineurin inhibitors have improved kidney transplant and recipient survival, their use has significant nephrotoxicity. Belatacept is a recently approved immunosuppressant that is not nephrotoxic…2015 American Transplant Congress
Belatacept-Treated Patients Had Better Graft Survival at 7-Years Post-Transplant Compared With Cyclosporine-Treated Patients: Final Results from BENEFIT
Background: At 3yrs, improvement in renal function was seen in kidney transplant recipients treated with belatacept (bela) vs cyclosporine (CsA) in BENEFIT. Here we report…2015 American Transplant Congress
Clinical Utility of Allospecific CD154+T-Cells in Children With Liver Or Intestine Transplantation (LTx, ITx)
Background: Allospecific CD154+T-cytotoxic memory (CD154+TcM) have completed investigational evaluation as predictors of acute cellular rejection in children with LTx or ITx.Purpose: To evaluate CD154+TcM** as…
- « Previous Page
- 1
- …
- 124
- 125
- 126
- 127
- 128
- …
- 138
- Next Page »